Threshold Halts Prostate Drug

Threshold Pharmaceuticals Inc. (THLD) halted development of its prostate drug TH-070 after it failed both mid-stage and late-stage clinical trials. The stock price plummeted more than 50% by falling $1.67 to $1.51.